Belite Bio initiated at Buy by Canaccord Genuity
Canaccord Genuity initiated coverage on Belite Bio with a Buy rating and set a $303.00 per-share price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.